Tempest Therapeutics, Inc. — Director's Dealing 2017

Sep 12, 2017

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: OvaScience, Inc. (OVAS)
CIK: 0001544227
Period of Report: 2017-09-01

Reporting Person: Kroeger Christopher A. (Director, Chief Executive Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$1.46	2027-06-21	Common Stock (1783106)		Direct

Footnotes

F1: The shares underlying this option vest (i) as to 267,466 of the shares on June 21, 2018; (ii) as to an aggregate of 802,398 of the shares in installments at the end of each successive three-month period following June 21, 2018 until June 21, 2021; (iii) as to 89,155 of the shares on January 31, 2019; (iv) as to an aggregate of 267,466 of the shares in installments at the end of each successive three-month period following January 31, 2019 until January 31, 2022; (v) as to 89,155 of the shares on January 31, 2020; and (vi) as to an aggregate of 267,466 of the shares in installments at the end of each successive three-month period following January 31, 2020 until January 31, 2023.